Product Description
Sorafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a607051.html)
Mechanisms of Action: TK Inhibitor, VEGFR Inhibitor, RAFk Inhibitor, PGFR Inhibitor, Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Costa Rica, Croatia, Czech Republic, Egypt, Estonia, Finland, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Korea, Malaysia, Philippines, Poland, Russia, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 18
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hepatocellular Carcinoma
Phase 2: Colorectal Cancer|Hepatitis A|Hepatitis B|Hepatitis C|Kidney Cancer|Liver Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01624285 |
NCI-2012-00911 | P2 |
Completed |
Liver Cancer|Hepatocellular Carcinoma |
2023-02-01 |
72% |
2023-12-15 |
|
ACTRN12620000849998 |
ACTRN12620000849998 | P2 |
Recruiting |
Colorectal Cancer|Non-Small-Cell Lung Cancer|Kidney Cancer|Liver Cancer |
2020-11-20 |
2026-03-03 |
Treatments |
|
NCT04710641 |
OUTREACH2 | P2 |
Completed |
Hepatitis A|Hepatocellular Carcinoma|Hepatitis B|Hepatitis C |
2025-01-25 |
42% |
2025-03-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04770896 |
IMbrave251 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2026-06-30 |
72% |
2026-02-18 |
|
NCT05068752 |
The Dr. Nate Nieto Study | P2 |
Active, not recruiting |
Pancreatic Cancer |
2024-10-30 |
30% |
2024-09-20 |
Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
NCT03439891 |
NCI-2018-00051 | P2 |
Completed |
Hepatocellular Carcinoma |
2023-11-30 |
31% |
2025-02-12 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03211416 |
I 35316 | P2 |
Completed |
Hepatocellular Carcinoma |
2023-03-07 |
12% |
2026-01-03 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05033522 |
ALIVE | P3 |
Suspended |
Hepatocellular Carcinoma |
2026-11-01 |
2025-10-24 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
jRCT2031210045 |
jRCT2031210045 | P3 |
Recruiting |
Hepatocellular Carcinoma |
2026-03-31 |
|||
2023-503229-21-00 |
MO42541 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
2025-06-13 |
2025-05-02 |
Treatments |
|
JapicCTI-205128 |
JapicCTI-205128 | P3 |
Active |
Unknown |
2023-09-16 |
|||
CTR20160605 |
CTR20160605 | P3 |
Active, not recruiting |
Hepatocellular Carcinoma |
None |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT06797427 |
DPH001-01 | P1 |
Completed |
Hepatocellular Carcinoma |
2025-03-10 |
12% |
2025-03-18 |
Primary Endpoints|Treatments|Trial Status |
CTR20170668 |
CTR20170668 | P3 |
Recruiting |
Hepatocellular Carcinoma |
None |
2025-04-29 |
||
JapicCTI-142709 |
JapicCTI-142709 | P1 |
Active |
Hepatocellular Carcinoma |
None |
|||
NCT06309485 |
WGI0301-P2G-01 | P2 |
Not yet recruiting |
Hepatocellular Carcinoma |
2026-08-01 |
30% |
2024-03-14 |
Primary Endpoints|Treatments |
CTR20202692 |
CTR20202692 | P2 |
Completed |
Hepatocellular Carcinoma |
2024-05-28 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT04000737 |
YIV-906-2018L1 | P2 |
Completed |
Hepatocellular Carcinoma |
2024-03-22 |
47% |
2025-04-15 |
Primary Endpoints |